ArticlePharmacoEconomics2016
Performance-Based Agreements in Italy: 'Trendy Outcomes' or Mere Illusions?
Article in PharmacoEconomics, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- Impact of Managed Entry Agreements on availability of and timely access to medicines: an ex-post evaluation of agreements implemented for oncology therapies in four countries.BMC health services research · 2022Article
- Pharmaceutical pricing in Europe: time to take the right direction.Internal and emergency medicine · 2022Article
- A MEA is a MEA is a MEA? Sequential decision making and the impact of different managed entry agreements at the manufacturer and payer level, using a case study for an oncology drug in England.The European journal of health economics : HEPAC : health economics in prevention and care · 2021Article
- Integrative Review of Managed Entry Agreements: Chances and Limitations.PharmacoEconomics · 2020Review
- Pharmaceutical expenditure control in Europe: time to move from pricing to budgeting?Journal of the Royal Society of Medicine · 2020Review
- Mapping of Current Obstacles for Rationalizing Use of Medicines (CORUM) in Europe: Current Situation and Potential Solutions.Frontiers in pharmacology · 2020Article
- Comparison of United States and International Ophthalmic Drug Pricing.Ophthalmology · 2019Observational
- Evolution of Average European Medicine Prices: Implications for the Methodology of External Price Referencing.PharmacoEconomics - open · 2019Article
- Multi-Indication Pricing: Nice in Theory but Can it Work in Practice?PharmacoEconomics · 2018Article
- Pharmaceutical pricing conundrum: time to get rid of it?The European journal of health economics : HEPAC : health economics in prevention and care · 2018Article
- The Implementation of Managed Entry Agreements in Central and Eastern Europe: Findings and Implications.PharmacoEconomics · 2017Article
- Adaptive Pathways: Possible Next Steps for Payers in Preparation for Their Potential Implementation.Frontiers in pharmacology · 2017Review
- How Risky Is That Risk Sharing Agreement? Mean-Variance Tradeoffs and Unintended Consequences of Six Common Risk Sharing Agreements.MDM policy & practiceArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
27260615What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.